Merck seeks more deals to prepare for Keytruda's revenue decline

[cafead]

via Merck & Co on Thursday said it was in the market for deals of up to around $15 billion as it plans for a loss of revenue from its aging cancer immunotherapy Keytruda, the world's top-selling prescription medicine.

article source